AI Engines For more Details: Perplexity Kagi Labs You
Cholesterol Reduction: Mevastatin works by inhibiting an enzyme called HMG-CoA reductase, which plays a key role in the production of cholesterol in the liver. By blocking this enzyme, mevastatin reduces the synthesis of cholesterol, leading to lower levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol.
Prevention of Atherosclerosis: Elevated levels of LDL cholesterol are a major risk factor for the development of atherosclerosis, a condition characterized by the buildup of plaque in the arteries. By lowering LDL cholesterol levels, mevastatin helps reduce the risk of atherosclerosis, which can lead to heart attack, stroke, and other cardiovascular complications.
Improvement of Cardiovascular Health: Lowering LDL cholesterol with mevastatin has been shown to reduce the incidence of cardiovascular events, including heart attack, stroke, and the need for revascularization procedures such as angioplasty or coronary artery bypass surgery. It can also help improve overall cardiovascular health and reduce mortality associated with cardiovascular disease.
Increase in High-Density Lipoprotein (HDL) Cholesterol: In addition to lowering LDL cholesterol, mevastatin may modestly increase levels of high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol. HDL cholesterol helps remove LDL cholesterol from the bloodstream, which further contributes to cardiovascular protection.
Anti-Inflammatory Effects: Statins like mevastatin have been found to have anti-inflammatory properties beyond their cholesterol-lowering effects. Chronic inflammation is associated with the development and progression of atherosclerosis, and statins may help reduce inflammation within the arterial walls, thereby slowing the progression of the disease.
Prevention of Cardiovascular Events: Mevastatin is commonly prescribed for individuals at high risk of cardiovascular events, such as those with coronary artery disease, diabetes, or other risk factors for cardiovascular disease. By reducing cholesterol levels and exerting other beneficial effects on the cardiovascular system, mevastatin can help prevent heart attacks, strokes, and related complications.
Side Effects: While mevastatin is generally well-tolerated, like other statins, it may cause side effects in some individuals. Common side effects may include muscle pain or weakness (myopathy), liver enzyme abnormalities, gastrointestinal symptoms (such as nausea, diarrhea, or constipation), and headache. Rare but serious side effects may include muscle breakdown (rhabdomyolysis) and liver toxicity.
Drug Interactions: Mevastatin may interact with other medications, particularly those metabolized by the same liver enzyme system, increasing the risk of side effects or reducing the effectiveness of either medication. It is important for healthcare providers to review the patient's medication regimen and monitor for potential drug interactions when prescribing mevastatin.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.6 | 0 |
| ADHD | 1.9 | 0.3 | 5.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1 | 0.3 | 2.33 |
| Allergies | 1.7 | 1.9 | -0.12 |
| Allergy to milk products | 0.9 | 0.7 | 0.29 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.8 | 4 | -1.22 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.3 | 2 |
| Ankylosing spondylitis | 2.1 | 0.9 | 1.33 |
| Anorexia Nervosa | 1 | 2.1 | -1.1 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 2 | 1.1 | 0.82 |
| Atherosclerosis | 0.7 | 1.6 | -1.29 |
| Atrial fibrillation | 2.3 | 1.7 | 0.35 |
| Autism | 3.9 | 4.7 | -0.21 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 1 | 1.1 | -0.1 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 0.3 | 0.3 | 0 |
| Carcinoma | 1.3 | 1 | 0.3 |
| Celiac Disease | 1.5 | 1.3 | 0.15 |
| Cerebral Palsy | 0.6 | 1.1 | -0.83 |
| Chronic Fatigue Syndrome | 1.7 | 3 | -0.76 |
| Chronic Kidney Disease | 1.3 | 2 | -0.54 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.4 | -0.4 |
| Chronic Urticaria (Hives) | 0.3 | 0.8 | -1.67 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.1 | -0.57 |
| Cognitive Function | 1.9 | 0.8 | 1.37 |
| Colorectal Cancer | 3.7 | 1.7 | 1.18 |
| Constipation | 1 | 0.5 | 1 |
| Coronary artery disease | 0.9 | 1.6 | -0.78 |
| COVID-19 | 1.7 | 5.3 | -2.12 |
| Crohn's Disease | 3 | 3 | 0 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 1.3 | 1.4 | -0.08 |
| Denture Wearers Oral Shifts | 0.7 | 0.7 | |
| Depression | 3.5 | 4.5 | -0.29 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.9 | -2 |
| Endometriosis | 1.3 | 1.4 | -0.08 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.7 | 0.9 | -0.29 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 1.2 | 2.2 | -0.83 |
| Functional constipation / chronic idiopathic constipation | 2.8 | 3.3 | -0.18 |
| gallstone disease (gsd) | 0.9 | 0.5 | 0.8 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.6 | -2 |
| Generalized anxiety disorder | 0.9 | 1.4 | -0.56 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.6 | 0.5 |
| Graves' disease | 1 | 1.7 | -0.7 |
| Gulf War Syndrome | 0.6 | 0.1 | 5 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.9 | 1.2 | 0.58 |
| Heart Failure | 2.1 | 1.1 | 0.91 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hyperglycemia | 0.4 | 0.7 | -0.75 |
| hypertension (High Blood Pressure | 2.4 | 2.3 | 0.04 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.7 | 0.7 | 0 |
| IgA nephropathy (IgAN) | 1.3 | 1.7 | -0.31 |
| Inflammatory Bowel Disease | 1.7 | 5.3 | -2.12 |
| Insomnia | 1.6 | 2 | -0.25 |
| Intelligence | 0.6 | 0.7 | -0.17 |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 2.2 | 2.6 | -0.18 |
| ischemic stroke | 1.3 | 1.1 | 0.18 |
| Liver Cirrhosis | 3 | 1.7 | 0.76 |
| Long COVID | 2.5 | 3.5 | -0.4 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.5 | 0.9 | -0.8 |
| ME/CFS without IBS | 0.3 | 0.9 | -2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 2.3 | 2.4 | -0.04 |
| Mood Disorders | 3.4 | 3.8 | -0.12 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.7 | |
| Multiple Sclerosis | 1.6 | 4.3 | -1.69 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 1.6 | -1.6 | |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 2 | 0.2 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 4.3 | 3 | 0.43 |
| obsessive-compulsive disorder | 2.2 | 2.4 | -0.09 |
| Osteoarthritis | 0.6 | 0.9 | -0.5 |
| Osteoporosis | 1.6 | 0.6 | 1.67 |
| pancreatic cancer | 0.3 | 0.6 | -1 |
| Parkinson's Disease | 3.6 | 4.2 | -0.17 |
| Polycystic ovary syndrome | 3.8 | 2 | 0.9 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 1 | 1.6 | -0.6 |
| Psoriasis | 0.7 | 3.1 | -3.43 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.7 | 1.6 | 1.31 |
| Rosacea | 0.9 | 0.5 | 0.8 |
| Schizophrenia | 1.9 | 2.1 | -0.11 |
| scoliosis | 0.3 | 0.8 | -1.67 |
| Sjögren syndrome | 1.4 | 1.1 | 0.27 |
| Sleep Apnea | 0.9 | 1.4 | -0.56 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 1.3 | 1.6 | -0.23 |
| Systemic Lupus Erythematosus | 1.4 | 1.3 | 0.08 |
| Tic Disorder | 0.7 | 0.7 | 0 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2 | 1.8 | 0.11 |
| Type 2 Diabetes | 3.1 | 2.4 | 0.29 |
| Ulcerative colitis | 1.5 | 2.8 | -0.87 |
| Unhealthy Ageing | 1.9 | 1.6 | 0.19 |
| Vitiligo | 1.7 | 1 | 0.7 |
